$PPHM Recent Headlines Peregrine plunges on test data

New Post Public Reply Private Reply Replies (0) Message Board

Jan 8, 2014 at 12:29 PM

$PPHM Recent Headlines

Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid

eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 3:23 p.m. May 21, 2012 - MarketWatch

Fast Track Status for Peregrine Candidate - Analyst Blog 5:20 p.m. Jan. 7, 2014 - Zacks.com
Peregrine Pharmaceuticals (PPHM) Soars: Stock Adds 14.5% in Session - Tale of the Tape 8:57 a.m. Jan. 7, 2014 - Zacks.com
Why Peregrine Pharmaceuticals (PPHM) is Surging 10:41 a.m. Jan. 6, 2014 - TheStreet.com
Peregrine Pharma Initiates Bavituximab Study - Analyst Blog 5:20 p.m. Dec. 31, 2013 - Zacks.com
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 6:37 a.m. Dec. 30, 2013 - benzinga.com
Consider Buy Rated Stocks Under Five Bucks as Stocking Stuffers 10:28 a.m. Dec. 23, 2013 - TheStreet.com
Peregrine Reports In-Line Loss - Analyst Blog 2:10 p.m. Dec. 11, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q2 2014 Results - Earnings Call Transcript 7:20 p.m. Dec. 10, 2013 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 5:34 p.m. Dec. 10, 2013 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 6.2% - Tale of the Tape 9:39 a.m. Nov. 22, 2013 - Zacks.com
The Race For A Cure For Cancer 1:44 p.m. Nov. 20, 2013 - Seeking Alpha
Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma 8:10 a.m. Nov. 8, 2013 - benzinga.com
Peregrine Pharmaceuticals is now in Oversold Territory - Tale of the Tape 7:06 a.m. Nov. 8, 2013 - Zacks.com
2013 Biotech Watchlist Update: Companies Climb And Crumble On Catalysts 10:48 a.m. Nov. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals' CEO Hosts Annual Meeting of Stockholders (Transcript) 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Peregrine Pharmaceuticals, Inc. - Shareholder/Analyst Call 8:00 p.m. Oct. 17, 2013 - Seeking Alpha
Biotech: Let's Make A Billion-Dollar Deal, Part 2 2:00 p.m. Oct. 1, 2013 - Seeking Alpha
Peregrine Pharmaceuticals Earnings: Here’s Why Investors are Not Excited Now 8:58 a.m. Sept. 10, 2013 - Wall St. Cheat Sheet
Peregrine Reports In-Line Loss - Analyst Blog 8:30 a.m. Sept. 10, 2013 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q1 2014 Results - Earnings Call Transcript 6:10 p.m. Sept. 9, 2013 - Seeking Alpha

Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer 7:30 a.m. Jan. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer 7:31 a.m. Dec. 30, 2013 - Marketwire
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial Results and Recent Developments 4:00 p.m. Dec. 10, 2013 - Marketwire
Peregrine Pharmaceuticals Announces Upcoming Events 4:00 p.m. Nov. 26, 2013 - Marketwire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
OXBT, HZNP, PPHM and NWBO added to NASDAQ Healthcare Stock Watch List at GSR 10:35 a.m. Nov. 11, 2013 - ACCESSWIRE
Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals' Novel Immunotherapy Bavituximab in Combination With Anti-CTLA-4 Antibodies 9:01 a.m. Nov. 8, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference 4:00 p.m. Nov. 5, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 3:03 p.m. Oct. 31, 2013 - PR Newswire
Symposium at IALSC World Conference on Lung Cancer to Highlight Novel Immune Checkpoints Including Peregrine Pharmaceuticals' Bavituximab PS Target 7:31 a.m. Oct. 15, 2013 - Marketwire
Pre-Market Review: Celgene Corp., Forest Laboratories Inc., Peregrine Pharma Inc., and Edwards Lifesciences Corp. 10:25 a.m. Oct. 9, 2013 - PR Newswire
Record Use of At-the-Market (ATM) Offerings by U.S. Life Sciences Companies in First Half of 2013, Reports Brinson Patrick 7:00 a.m. Sept. 17, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments 3:00 p.m. Sept. 9, 2013 - Marketwire
Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research 7:31 a.m. Sept. 9, 2013 - Marketwire
Early Briefing and Review: Celgene Corp., Edwards Lifesciences Corp., Forest Laboratories Inc., and Peregrine Pharma Inc. 4:11 p.m. Sept. 6, 2013 - PR Newswire
Peregrine to Report First Quarter Fiscal Year 2014 Financial Results After Market Close on September 9, 2013 3:06 p.m. Sept. 3, 2013 - Marketwire
Bavituximab's Mechanism of Action Highlighted at Immunomodulatory Therapeutic Antibodies for Cancer Conference 2:01 p.m. Aug. 14, 2013 - Marketwire
Peregrine Pharmaceuticals to Present at Upcoming Conferences 3:00 p.m. Aug. 6, 2013 - Marketwire
Morning Research: Celgene, Edwards Lifesciences, Forest Laboratories, and Peregrine Pharma 8:12 a.m. July 31, 2013 - PR Newswire
Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments 3:06 p.m. July 11, 2013 - Marketwire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CelluPro Earns Global Recognition with EXCiPACT Certification

Breaking New Ground with EXCiPACT Certification Here's a tale unfolding in the high-stakes world of biotechnology—CelluPro, a standout in cell culture media, just snagged the EXCiPACT™ certification. This isn't just some fancy plaque for the wall. It's a stamp of approval that screams reliability in the global biomanufacturing supply scene. Why This Certification...

$Aluminum Refractory Market to Hit $2.73B by 2031$

Riding the Aluminum Refractory Wave to 2031 Look, when you want to throw some cash in a market that's gaining steam, aluminum refractory materials might not be your first pick. But here's the thing: it's charging ahead to a cool $2.73 billion by 2031. And if you're keeping tabs on the likes of RHI Magnesita and Calderys, this is a sector that deserves a once-over. What...

Nutromics Welcomes Plaxco: Strategic Tech Leap Forward

Professor Plaxco’s Dynamic Role at Nutromics Some folks start their day with breakfast and coffee, but Nutromics is grabbing headlines by introducing Professor Kevin Plaxco as the new Chief Scientific Officer. This strategic shift, made public on September 7, 2026, signals Nutromics’ ambition to amplify its DNA-based sensing footprint. As they gear up to launch their...

Thermoplastic Polyimide: A $0.86 Billion Market by 2032

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

Nurminen Logistics Doubles Sweden–Italy Rail Capacity

Nurminen Logistics Betting Big on Rail Expansion Feeling the pulse of the logistics world is much like trying to catch lightning in a bottle, but Nurminen Logistics seems to have found its rhythm. They're ramping up their services between Sweden and Italy, leveraging rail to push the envelope. Come October, they're doubling down from one to two weekly departures, giving...

Early Orders Key for Custom Kids' Gifts This Season

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

Indiana Fire Safety: The Importance of Regular Inspections

Everybody thinks of fire extinguishers as those red cans hanging quietly on walls, but there's more to them than meets the eye. In Central Indiana, these devices are a literal lifeline, and neglecting their upkeep is playing with fire—literally. What Makes Monthly Checks a Big Deal? Fire extinguishers aren't just there for decoration. They're critical safety gear. This...

U.S. Court Ruling Opens Market for Cocrystal's CrysQnol™

Legal Drama Clears Market Path Well, folks, here’s a win from the trenches for Cocrystal Tech that can shake up the nutraceutical market. Kaneka's grip on the patent for their ubiquinol concoctions just got busted by the U.S. District Court. They ruled that Kaneka's claims lacked utility and enablement, essentially saying they were pitching an untested hypothesis as an...

FOTON Accelerates Global Push with European Focus

The Road to Global Dominance Ever feel like someone’s racing past you while others try to catch up? That’s FOTON in the relentless world of commercial vehicles. This juggernaut of a company isn't just satisfied with leading the pack; they’ve got their eyes set on redefines the game, especially with their new moves in Europe. A Shift in Strategy Right now, the...

Huayan Robotics Hits IMTS 2026 with Cutting-Edge Tech

Unveiling Robotics Prowess at IMTS 2026 Every two years, the world of manufacturing gathers at the International Manufacturing Technology Show (IMTS), and this time, the spotlight is on Huayan Robotics. With the event drawing over 90,000 professionals, everybody with a finger on the pulse of intelligent manufacturing will be keen to see what Huayan has up its sleeve. This...